A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate
Public ClinicalTrials.gov record NCT00644631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To compare the effects of sildenafil versus placebo on the female partner's sexual satisfaction as assessed by Question 3 of Female Partner of Erectile Dysfunction (ED) Subject Questionnaire (FePEDS-Q): "Over the past 4 weeks, when you had sexual intercourse, how often was it satisfactory for you?" For ED subjects, determine difference in the Erectile Function domain of International Index of Erectile Function (IIEF) between sildenafil citrate and placebo at end of the treatment phase and determine the overall relationship between improved erectile function and increased ED subject and female partner satisfaction.
Study identification
- NCT ID
- NCT00644631
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Apr 2004 (Actual)
- Last update posted
- Feb 1, 2021
2003 – 2004
United States locations
- U.S. sites
- 31
- U.S. states
- 20
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Huntsville | Alabama | 35801 | — |
| Pfizer Investigational Site | Little Rock | Arkansas | — | — |
| Pfizer Investigational Site | Beverly Hills | California | 90212 | — |
| Pfizer Investigational Site | Laguna Woods | California | 92653 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Los Angeles | California | 90073 | — |
| Pfizer Investigational Site | Palo Alto | California | 94305 | — |
| Pfizer Investigational Site | Torrance | California | 90505 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80012 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06708 | — |
| Pfizer Investigational Site | Ocala | Florida | 34474 | — |
| Pfizer Investigational Site | Peoria | Illinois | 61614 | — |
| Pfizer Investigational Site | Jeffersonville | Indiana | 47130 | — |
| Pfizer Investigational Site | Des Moines | Iowa | 50314 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66215 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21204 | — |
| Pfizer Investigational Site | Peabody | Massachusetts | 01960 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63117 | — |
| Pfizer Investigational Site | Garden City | New York | 11530 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Poughkeepsie | New York | 12601 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27705 | — |
| Pfizer Investigational Site | Beachwood | Ohio | 44122-5402 | — |
| Pfizer Investigational Site | Newtown | Pennsylvania | 18940 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37920 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Lacey | Washington | 98516 | — |
| Pfizer Investigational Site | Seattle | Washington | 98105 | — |
| Pfizer Investigational Site | Spokane | Washington | 99207 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00644631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2021 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00644631 live on ClinicalTrials.gov.